MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 535008 | Name: Sulmepride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Sulmepride is a bioactive chemical.

Chemical Structure

Sulmepride
Sulmepride
CAS#57479-88-6

Theoretical Analysis

MedKoo Cat#: 535008

Name: Sulmepride

CAS#: 57479-88-6

Chemical Formula: C14H21N3O4S

Exact Mass: 327.1253

Molecular Weight: 327.40

Elemental Analysis: C, 51.36; H, 6.47; N, 12.83; O, 19.55; S, 9.79

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Sulmepride
IUPAC/Chemical Name
Benzamide, 5-(aminosulfonyl)-2-methoxy-N-((1-methyl-2-pyrrolidinyl)methyl)-
InChi Key
QCKAYJICSQJJCU-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H21N3O4S/c1-17-7-3-4-10(17)9-16-14(18)12-8-11(22(15,19)20)5-6-13(12)21-2/h5-6,8,10H,3-4,7,9H2,1-2H3,(H,16,18)(H2,15,19,20)
SMILES Code
O=C(NCC1N(C)CCC1)C2=CC(S(=O)(N)=O)=CC=C2OC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 327.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Silvestre FJ, Silvestre-Rangil J, López-Jornet P. Burning mouth syndrome: a review and update. Rev Neurol. 2015 May 16;60(10):457-63. English, Spanish. PMID: 25952601. 2: Smith RC, Leucht S, Davis JM. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. Psychopharmacology (Berl). 2019 Feb;236(2):545-559. doi: 10.1007/s00213-018-5133-z. Epub 2018 Nov 30. PMID: 30506237. 3: Kahn RS, Winter van Rossum I, Leucht S, McGuire P, Lewis SW, Leboyer M, Arango C, Dazzan P, Drake R, Heres S, Díaz-Caneja CM, Rujescu D, Weiser M, Galderisi S, Glenthøj B, Eijkemans MJC, Fleischhacker WW, Kapur S, Sommer IE; OPTiMiSE study group. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry. 2018 Oct;5(10):797-807. doi: 10.1016/S2215-0366(18)30252-9. Epub 2018 Aug 13. PMID: 30115598. 4: Howard R, Cort E, Bradley R, Harper E, Kelly L, Bentham P, Ritchie C, Reeves S, Fawzi W, Livingston G, Sommerlad A, Oomman S, Nazir E, Nilforooshan R, Barber R, Fox C, Macharouthu A, Ramachandra P, Pattan V, Sykes J, Curran V, Katona C, Dening T, Knapp M, Romeo R, Gray R. Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. Health Technol Assess. 2018 Nov;22(67):1-62. doi: 10.3310/hta22670. PMID: 30507375; PMCID: PMC6304731. 5: Howard R, Cort E, Bradley R, Harper E, Kelly L, Bentham P, Ritchie C, Reeves S, Fawzi W, Livingston G, Sommerlad A, Oomman S, Nazir E, Nilforooshan R, Barber R, Fox C, Macharouthu AV, Ramachandra P, Pattan V, Sykes J, Curran V, Katona C, Dening T, Knapp M, Gray R; ATLAS Trialists Group. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial. Lancet Psychiatry. 2018 Jul;5(7):553-563. doi: 10.1016/S2215-0366(18)30141-X. Epub 2018 Jun 4. Erratum in: Lancet Psychiatry. 2018 Jun 12;: PMID: 29880238; PMCID: PMC6015223. 6: Horikomi K, Fujita M. [Comparative study of the pharmacological properties of sultopride sulpiride and other antipsychotic drugs: influence of sultopride, sulpiride and other antipsychotic drugs on spontaneous locomotor activity and changes in locomotor activity induced by apomorphine and clonidine in mice]. Yakubutsu Seishin Kodo. 1986 Sep;6(3):339-52. Japanese. PMID: 2880435. 7: Men P, Yi Z, Li C, Qu S, Xiong T, Yu X, Zhai S. Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis. BMC Psychiatry. 2018 Sep 5;18(1):286. doi: 10.1186/s12888-018-1867-8. PMID: 30185173; PMCID: PMC6125952. 8: Admon R, Kaiser RH, Dillon DG, Beltzer M, Goer F, Olson DP, Vitaliano G, Pizzagalli DA. Dopaminergic Enhancement of Striatal Response to Reward in Major Depression. Am J Psychiatry. 2017 Apr 1;174(4):378-386. doi: 10.1176/appi.ajp.2016.16010111. Epub 2016 Oct 24. PMID: 27771973; PMCID: PMC5378658. 9: Mizuchi A, Kitagawa N, Miyachi Y. Regional distribution of sultopride and sulpiride in rat brain measured by radioimmunoassay. Psychopharmacology (Berl). 1983;81(3):195-8. doi: 10.1007/BF00427261. PMID: 6417707. 10: Habib AS, Kranke P, Bergese SD, Chung F, Ayad S, Siddiqui N, Motsch J, Leiman DG, Melson TI, Diemunsch P, Fox GM, Candiotti KA. Amisulpride for the Rescue Treatment of Postoperative Nausea or Vomiting in Patients Failing Prophylaxis: A Randomized, Placebo-controlled Phase III Trial. Anesthesiology. 2019 Feb;130(2):203-212. doi: 10.1097/ALN.0000000000002509. PMID: 30475232. 11: Sekhar GN, Fleckney AL, Boyanova ST, Rupawala H, Lo R, Wang H, Farag DB, Rahman KM, Broadstock M, Reeves S, Thomas SA. Region-specific blood-brain barrier transporter changes leads to increased sensitivity to amisulpride in Alzheimer's disease. Fluids Barriers CNS. 2019 Dec 17;16(1):38. doi: 10.1186/s12987-019-0158-1. PMID: 31842924; PMCID: PMC6915870. 12: Mizuchi A, Kitagawa N, Saruta S, Miyachi Y. Characteristics of [3H]sultopride binding to rat brain. Eur J Pharmacol. 1982 Oct 15;84(1-2):51-9. doi: 10.1016/0014-2999(82)90156-x. PMID: 6128237. 13: Kranke P, Bergese SD, Minkowitz HS, Melson TI, Leiman DG, Candiotti KA, Liu N, Eberhart L, Habib AS, Wallenborn J, Kovac AL, Diemunsch P, Fox G, Gan TJ. Amisulpride Prevents Postoperative Nausea and Vomiting in Patients at High Risk: A Randomized, Double-blind, Placebo-controlled Trial. Anesthesiology. 2018 Jun;128(6):1099-1106. doi: 10.1097/ALN.0000000000002133. PMID: 29543631. 14: Gan TJ, Kranke P, Minkowitz HS, Bergese SD, Motsch J, Eberhart L, Leiman DG, Melson TI, Chassard D, Kovac AL, Candiotti KA, Fox G, Diemunsch P. Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials. Anesthesiology. 2017 Feb;126(2):268-275. doi: 10.1097/ALN.0000000000001458. PMID: 27902493. 15: Düring SW, Nielsen MØ, Bak N, Glenthøj BY, Ebdrup BH. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade - An exploratory study. Psychiatry Res. 2019 Apr;274:58-65. doi: 10.1016/j.psychres.2019.02.017. Epub 2019 Feb 8. PMID: 30780063. 16: Mizuchi A, Saruta S, Kitagawa N, Miyachi Y. Development of radioimmunoassay for sultopride and sulpiride. Arch Int Pharmacodyn Ther. 1981 Dec;254(2):317-26. PMID: 7337503. 17: Tollens F, Gass N, Becker R, Schwarz AJ, Risterucci C, Künnecke B, Lebhardt P, Reinwald J, Sack M, Weber-Fahr W, Meyer-Lindenberg A, Sartorius A. The affinity of antipsychotic drugs to dopamine and serotonin 5-HT2 receptors determines their effects on prefrontal-striatal functional connectivity. Eur Neuropsychopharmacol. 2018 Sep;28(9):1035-1046. doi: 10.1016/j.euroneuro.2018.05.016. Epub 2018 Jul 10. PMID: 30006253. 18: Lertxundi U, Erezuma I, Hernandez R, Medrano J, Garcia M, Aguirre C. Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance). Int Clin Psychopharmacol. 2019 Mar;34(2):89-92. doi: 10.1097/YIC.0000000000000247. PMID: 30531551. 19: Moriuchi K, Imazu Y, Yoneda H. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain. Neurochem Res. 1995 Jan;20(1):95-9. doi: 10.1007/BF00995158. PMID: 7739765. 20: Kobari T, Namekawa H, Kato Y, Yamada S. Biotransformation of sultopride in man and several animal species. Xenobiotica. 1985 Jun;15(6):469-76. doi: 10.3109/00498258509045020. PMID: 4036171.